(Total Views: 506)
Posted On: 04/29/2020 5:53:46 PM
Post# of 154910
“Gilead wants nothing to do with us side by side with Remdesivir.”
If i embers correctly, NP said a week or two ago that they were approached about a study combining remdesivir and leronlimab in a trial for COVID19. Now, was that Gilead that approached them or a 3rd party? We may never know, but it sounds like an opportunity was there. Leronlimab looks very promising for COVID, but trial enrollment is going at a snails pace because of CYDY’s small staff size and even smaller budget. Partnering with a drug like remdesivir could speed those trials up. Especially the severe trial, which may never enroll at its current pace.
If i embers correctly, NP said a week or two ago that they were approached about a study combining remdesivir and leronlimab in a trial for COVID19. Now, was that Gilead that approached them or a 3rd party? We may never know, but it sounds like an opportunity was there. Leronlimab looks very promising for COVID, but trial enrollment is going at a snails pace because of CYDY’s small staff size and even smaller budget. Partnering with a drug like remdesivir could speed those trials up. Especially the severe trial, which may never enroll at its current pace.
(1)
(0)
